



Bringing fast & accurate molecular testing closer to the patient

Focused on unmet needs in a critical niche



Based in St. George, Utah

The GeneSTAT® System

FDA-Cleared for Valley Fever

Proprietary GeneSTAT® Diagnostic Instrument

Definitive molecular testing that is
rapid and easy to use




Proprietary GeneSTAT® Test Cartridge

FDA-Clearance for Valley Fever tests
with pipeline of tests for expansion



Valley Fever Patient Journey | Current Testing



Patient impact — Up to 5 months for correct diagnosis

- 1 month lost work
- \$22,000 - \$50,000 hospital stay (3 medical visits including hospital stay on average)
- Chronic or disseminated disease due to delayed diagnostics

Potential Patient Journey | GeneSTAT® Diagnostic

One Day Diagnosis

Patient presents with symptoms of pneumonia

- Test for Valley Fever can be done on-site

Definitive diagnosis reached

- Correct treatment administered
- Recovery begins immediately

The Only FDA-Cleared Molecular Definitive
Diagnostic Test for Valley Fever Available Today

Current Testing vs. GeneSTAT® Diagnostics

Current



Definitive Diagnosis
Direct Health Care Costs
Physician Experience
Patient Health Impact

5 months	Same day
\$22k - \$50K	~ \$5,000
Uncertain results	Definitive answer
Chronic diagnosis with lifetime costs	Full recovery more likely


We're Only Scratching the Surface

NOW: Valley Fever Testing

- Market Entry - \$35M
- Market Opportunity - \$70M

NEXT: Novel MRSA+ Test — Beta Testing Complete

- Market Opportunity - \$2B
- Additional Unique Products in Pipeline



- Untapped Market Potential
- Valley Fever Testing

Achievements to Date



- FDA Cleared Valley Fever Test on The GeneSTAT® System
- ISO Certified manufacturing facility
- Strong IP portfolio
- Proven & Experienced management team
- First lab commitment in place



Current Pursuits

- Securing additional labs in the endemic area (AZ, CA, TX)
- Ramping up manufacturing capabilities
- Preparing our marketing & sales strategy for launch
- Anticipate recurring revenue stream within 6 months



Future Opportunities

- Secure additional equity capital to achieve the objectives above
 - Pursue NIH SBIR grants for Valley Fever & MRSA+ development
 - Continue to market the GeneSTAT® instrument and Valley Fever tests
 - Develop a unique pipeline of tests, starting with MRSA+
 - Pursue CE Mark & FDA - Clearance for MRSA+
 - Continue product & business development in both Valley Fever and MRSA+





Thank you



GeneSTAT
RAPID DNA TESTING